P3-198 - Efficacy and safety of megestrol acetate plus zusanli(ST 36) point injection in the prevention of CINV

Abstract

Background: To explore the therapeutic effect on chemotherapy-induced nausea and vomitting and side effect with megestrol acetate plus zusanli(ST 36) point injection. Methods: 180 cases of NSCLC patient were randomly divided into four groups. Group control (group C) received placebo plus sham point injection. Group megestrol acetate (group M) recieved megestrol acetate plus sham point injection.Group zusanli(ST 36) point injection (group Z) received placebo plus zusanli(ST 36) point injection. Group megestrol acetate combined with zusanli(ST 36) point injection (group M+Z) received megestrol acetate plus zusanli(ST 36) point injection. Results: In the acute phase, group M+Z was effective as group M(92.9%vs93.0%, P = 0.976), and more effective than either group Z(92.9%vs69.8%, P = 0.006;93.0%vs69.8%, P = 0.006) or group C(92.9%vs70.5%, P = 0.008;88.01%vs80.58%, P = 0.007). There was no statistical difference between group Z and group C(69.8%vs70.5%, P = 0.944). The complete control rates were similar in the four groups with no significant difference(P = 0.950). In the delayed phase, group M+Z was more effective than group C, M, Z(85.7%vs29.5%, P = 0.000; 85.7%vs58.1%, P = 0.005; 85.7%vs58.1%, P = 0.005). Group M and Z were more effective than group C(58.1%vs29.5%, P = 0.007; 58.1%vs29.5%, P = 0.007). The complete control rates of group M+Z were higher than group C,M and Z(59.5%vs27.3, P = 0.003;59.5%vs27.9%, P = 0.003;59.5%vs30.2, P = 0.007). There was no statistical difference between group C, M and Z with similar complete control rates(P > 0.05). The adverse effects of each group were mild. Conclusions: Megestrol acetate plus zusanli(ST 36) point injection was shown to be effective and safe. This might be a new antiemetic option for chemotherapy.